Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Wai-Shan Lam who wrote (862)	4/29/1998 2:45:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

From a technical perspective BTIM is resting right around or just below what should be longterm support at 9-10. The intraday 8 1/5 does not worry me. It has traded steadily down from 16 to 10 and has yet to make a reaction to this slide. It will at some point. Perhaps shorts will see this as their point to cover and drive the price up. I think selling at this point is a mistake. If you want to get out then wait for another rally. Jim

To: Wai-Shan Lam who wrote (862)	4/29/1998 2:53:00 PM
From: CatLady	Read Replies (2) \| Respond to of 1432

I'd suggest that you go to Asensio's web site, look at the other past reports on-line, then compare the price action on a chart to when the report was published. Then make your own decision. I think that his reports do move stock prices. Just like buy-side analysts can move prices with their recommendations.

To: Wai-Shan Lam who wrote (862)	4/29/1998 3:47:00 PM
From: john w. toigo	Read Replies (1) \| Respond to of 1432

Hard to give a "good" reason in this market that is probably past its near term top. I was originally short this stock at 60ish then flipped and went long a small position after the split and first correction. Biotechs are not for the faint-of-heart, but the rewards can be huge. i don't place that much value in the Abbott position-the $$ are pocket change to them. My view is that the upside potential is large because of the problems with the worldwide blood supply shortage and the cost of giving plasma and/or whole blood during surgical cases. Also, I think the military uses are significant. On the other side, look at the trouble Baxter has had with their blood substitute-huge studies and still no approval but its a different animal because of the O2 carrying indication of the Baxter product. It's a tough call on this one.